Literature DB >> 25425293

Diagnostic Performance of an Anti-Actin Autoantibody Binding Enzyme Immunodot Blot in Autoimmune Hepatitis Type 1.

Heiko Schotte1, Peter Willeke2, Johanna Schmalhorst3, Bernhard Schlüter3.   

Abstract

BACKGROUND: A serologic hallmark of autoimmune hepatitis (AIH) type 1 are anti-smooth muscle autoantibodies (ASMA) with specificity for filamentous actin (F-actin; AAA (anti-actin antibodies)), traditionally detected by indirect immunofluorescence (IFT) using rat liver, kidney, and stomach tissue sections as substrates. However, IFT is a subjective method requiring an experienced investigator. Therefore, a more objective technique for the detection of AAA may be a helpful diagnostic tool.
METHODS: In a retrospective study with cross-sectional design, we evaluated AAA detected by an enzyme immunodot blot (IDB; Liver5 IgG BlueDot, D-tek, Mons, Belgium). Serum samples of patients with AIH type 1 (n = 47) and specified controls (n = 142) were included. For comparison, standard IFT was applied to rat LKS (liver, kidney, stomach) triple tissue sections.
RESULTS: IDB readings were done by two independent investigators (92% concordance). The diagnostic sensitivity of the AAA-IDB was 70%, compared to 51% of AAA-IFT (n.s.). The diagnostic specificity of AAA-IDB was significantly lower compared to AAA-IFT (76% vs. 94%; P < 0.0005). Correspondingly, the positive predictive value (49% vs. 75%; P < 0.05) and positive likelihood ratio (2.9 vs. 8.5) differed significantly. Neither prescreening for ANA or ASMA, nor the exclusion of infectious hepatopathies resulted in a significantly better diagnostic performance of the IDB.
CONCLUSION: Compared to standard IFT, testing for AAA via IDB did not result in a significantly better diagnostic performance for AIH type 1. A blot with higher antigen binding specificity may be more functional.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-actin autoantibodies; autoimmune hepatitis type 1; enzyme immunodot blot

Mesh:

Substances:

Year:  2014        PMID: 25425293      PMCID: PMC6806702          DOI: 10.1002/jcla.21825

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

1.  Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA.

Authors:  A Zamanou; A Tsirogianni; C Terzoglou; A Balafas; I Economidou; P Lymberi
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Diagnosis and management of autoimmune hepatitis.

Authors:  Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 3.  Autoimmune hepatitis.

Authors:  Edward L Krawitt
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

4.  Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis.

Authors:  Christian Frenzel; Johannes Herkel; Stefan Lüth; Peter R Galle; Christoph Schramm; Ansgar W Lohse
Journal:  Am J Gastroenterol       Date:  2006-12       Impact factor: 10.864

5.  Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group.

Authors:  R Jaeschke; G H Guyatt; D L Sackett
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

6.  Anti-actin antibodies: a new test for an old problem.

Authors:  M Fusconi; F Cassani; D Zauli; M Lenzi; G Ballardini; U Volta; F B Bianchi
Journal:  J Immunol Methods       Date:  1990-06-12       Impact factor: 2.303

7.  Diagnostic value of anti-F-actin antibodies in a French multicenter study.

Authors:  P Chretien-Leprince; E Ballot; C Andre; N O Olsson; N Fabien; A Escande; F Oksman; S Dubuquoi; S Jego; J Goetz; A Chevailler; M Sanmarco; R L Humbel; C Johanet
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

8.  Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.

Authors:  J C Homberg; N Abuaf; O Bernard; S Islam; F Alvarez; S H Khalil; R Poupon; F Darnis; V G Lévy; P Grippon
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

9.  Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis.

Authors:  Vaibhav Mehendiratta; Pradnya Mitroo; Alessandro Bombonati; Victor J Navarro; Simona Rossi; Raphael Rubin; Steven K Herrine
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-12       Impact factor: 11.382

10.  Autoantibodies and circulating immune complexes in sera from patients with hepatitis B virus-related chronic liver disease.

Authors:  H Louzir; T Ternynck; Y Gorgi; S Tahar; K Ayed; S Avrameas
Journal:  Clin Immunol Immunopathol       Date:  1992-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.